Randomised Study of High-dose Epirubicin Versus High-dose Epirubicin-Cisplatin Chemotherapy for Advanced Soft Tissue Sarcoma

By Jelic S.   Kovcin V.   Milanovic N.   Babovic N.   Kreacic M.   Ristovic Z.   Vlajic M.   Filipovic-Ljeskovic I.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 220-225

Elsevier

Access to resources Recommend Favorite

Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer

By Yahata Hideaki   Hirakawa Toshio   Fujita Takuji   Ariyoshi Kazuya   Sonoda Kenzo   Amada Satoshi   Kobayashi Hiroaki   Nakano Hitoo  

International Journal of Clinical Oncology, Vol. 9, Iss. 4, 2004-08 ,pp. : 317-321

Springer Publishing Company

Access to resources Recommend Favorite

Epirubicin, Cisplatin, and Prolonged or Brief Infusional 5-Fluorouracil in the Treatment of Carcinoma of Unknown Primary Site

By Karapetis C.S.   Yip D.   Virik K.   Strickland A.   Ryder K.   Cowling M.   Harper P.G.  

Medical Oncology, Vol. 18, Iss. 1, 2001-03 ,pp. : 23-32

Humana Press, Inc

Access to resources Recommend Favorite

Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial - an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study

By Pectasides D.   Visvikis A.   Aspropotamitis A.   Halikia A.   Karvounis N.   Dimitriadis M.   Athanassiou A.  

European Journal of Cancer, Vol. 36, Iss. 1, 2000-01 ,pp. : 74-79

Elsevier

Access to resources Recommend Favorite

Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma

By                

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 1017-1022

Spandidos Publications

Access to resources Recommend Favorite